Biomarkers

Blogs

Multiplex Tissue Analysis + Digital Pathology in Clinical Research – A Summary of ASCO 2021 Findings

Background The range of technologies that enable multiplex tissue analysis (MTA) and digital pathology (DigPath) are rapidly growing and entering the clinical research space, providing new means of characterizing the

The Galaxy’s Guardians with Dr. Chris Mason

I recently had a chance to sit down for a really fun conversation with my friend Dr. Chris Mason. Chris is a professor at Weill Cornell Medicine, and he works

Navigating Companion Diagnostics (CDx) – Multiple Stakeholders, Many Goals

Background Companion diagnostic (CDx) tests are a foundational tool in precision medicine, helping ensure only the right patients receive the right therapies. The past several years have seen an explosion

AGBT 2021 Catch-Up with Jeffrey Rosenfeld

  Jeffrey Rosenfeld, Ph.D. has extensive experience in genomics and bioinformatics. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including

Update on the Adoption And Utilization of Emerging Precision Medicine Biomarkers and Technologies in Routine Clinical Care

At DeciBio Consulting, our mission is to provide market intelligence and insights to advance precision medicine.  To this end, we track this space closely, especially the field of precision oncology,

DeciBio’s Q&A with Brady Davis, SVP of Business Development for Canexia Health

  DeciBio had the pleasure of interviewing Canexia Health’s SVP of Business Development, Brady Davis. We interviewed Brady to understand how Canexia Health and Project ACTT (Access to Testing and

‘Digital Contact Tracing’ — Advantages, Risks, & Post-COVID Applications

  While Apple & Google’s technology holds promise over traditional contact tracing and other, less privacy-friendly methods of digital surveillance being used across the globe, perceived data privacy and security

Cancer Immunotherapy Biomarker Spotlight: Immune Function Markers / Analyses

We’ve been tracking the cancer immunotherapy biomarker space closely via our Immuno-Oncology BioMAP for years and have witnessed the rapid growth and evolution of immuno-oncology first hand.  The amount of

A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers

We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light